Colorectal Cancer Metastatic MSI-High Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Micros

Brief description of study

If you have been diagnosed with Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer, you may qualify for this Phase 3 study. The main goal of this study is to learn if adding an experimental drug, atezolizumab (MPDL3280A), to a usual treatment or giving the experimental drug alone is better than the usual treatment (the chemotherapy drugs, 5-flouorouracil (5-FU), leucovorin, and oxaliplatinalone) alone.

Clinical Study Identifier: s17-01835 Identifier: NCT02997228
Principal Investigator: Daniel J Becker.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.